3,3-dimethylthiane | 57259-83-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: 3,3-dimethylthiane
• 英文别名: 3,3-dimethyl-tetrahydro-thiopyran；3,3-dimethyl-thiane；3.3-Dimethylthian；3,3-Dimethyl-thiacyclohexane
• CAS: 57259-83-3
• 化学式: C₇H₁₄S
• 分子量: 130.254
• InChiKey: VTTAITZGCXLKBP-UHFFFAOYSA-N

物化性质

• 沸点：
  166.3±9.0 °C(Predicted)
• 密度：
  0.902±0.06 g/cm3(Predicted)
• 保留指数：
  989

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,2-二甲基戊二酸 在 sodium sulfide 、 lithium aluminium tetrahydride 、 溴 、 三苯基膦 作用下， 以 乙醚 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 3,3-dimethylthiane
  参考文献：
  名称：

  Dependence of the γ carbon-13 shielding effect on electronegativity

  摘要：

  AbstractThree γ effects on 13C shielding in 3,3‐dimethylheteracyclohexanes as a function of the hetero‐atom X have been examined. The γ‐anti effect on the equatorial 3‐methyl group is small in absolute magnitude but strongly dependent on the polar properties of X. The plot of the 13C shielding of this carbon vs the electronegativity of X is linear, with a slope of −5.8 ppm/electronegativity unit. The γ‐gauche effects on the axial 3‐methyl group and on the 4‐carbon are large in absolute magnitude but have quite different dependences on the polar properties of X. Whereas the shielding of the 4‐carbon exhibits a linear dependence on electronegativity (slope −3.5), the axial 3‐methyl group shows little dependence (slope crudely −0.7), even though the geometric relationship between X and either carbon is almost the same. Neither gauche carbon shielding appears to be related to the steric properties of X. The polar component of both the γ‐anti effect and the γ‐gauche effect is interpreted as arising from overlap of appropriately positioned parallel orbitals. For the anti case, the pathway is the familiar zigzag arrangement of bonds. For the gauche case, the pathway may be either through space (the orbitals would be only on X and C‐α; for the 4‐carbon, this interaction would be through the center of the ring) or through bonds (there are parallel axial orbitals on all four atoms). The absence of a significant polar effect for the axial 3‐methyl group suggests that the gauche interaction requires a rigid pathway. The polar component of the general γ‐gauche effect is superimposed upon a larger contribution that is essentially independent of the nature of X and may be associated with the removal of the hydrogen on the β‐carbon and replacement with the γ‐X group.

  DOI：

  10.1002/mrc.1270170410

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Prodrugs of GABA analogs, compositions and uses thereof
  申请人：——

  公开号：US20040077553A1

  公开（公告）日：2004-04-22

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，GABA类似物前药的药物组合物以及制备GABA类似物前药的方法。本发明还提供了使用GABA类似物前药的方法，以及使用GABA类似物前药的药物组合物治疗或预防常见疾病和/或疾病的方法。
• Modulators of ATP-binding cassette transporters
  申请人：Hadida Ruah S. Sara

  公开号：US20070244159A1

  公开（公告）日：2007-10-18

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作调节ATP结合盒（“ABC”）转运蛋白或其片段的工具，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Spirocyclic nitriles as protease inhibitors
  申请人：Schudok Manfred

  公开号：US20090275523A1

  公开（公告）日：2009-11-05

  The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.

  这项发明涉及公式Ia的取代碳氢和杂环螺环化合物，其抑制硫醇蛋白酶，以及它们的制备方法和用作药物的用途。